Peter Guenter
Fortune : 13 754 $ au 31/07/2026
Fortune : 13 754 $ au 31/07/2026
Peter Guenter is currently Director at Ipsen SA since 2026, Director at Vicore Pharma Holding AB since 2026, and Director at the European Federation of Pharmaceutical Industries & Assns.
Formerly, Mr. Guenter was Chief Executive Officer & Director at Almirall SA from 2017 to 2020, Member-Management Board & CEO-Healthcare at Merck KGaA from 2021 to 2025, Chief Executive Officer at Merck Healthcare KGaA, Chairman-Supervisory Board at Sanofi-Aventis Deutschland GmbH, Independent Non-Executive Director at Lakefront Biotherapeutics from 2019 to 2025, EVP, General Manager-Diabetes & Cardiovascular at Sanofi from 2013 to 2017, and Executive Vice President at Smithkline Beecham.
Education includes graduation from Ghent University.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/12/2025 | 501 ( 0 % ) | 13 754 $ | 31/07/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| IPSEN | Directeur/Membre du Conseil | 28/01/2026 |
| VICORE PHARMA HOLDING AB | Directeur/Membre du Conseil | 07/05/2026 |
European Federation of Pharmaceutical Industries & Assns
European Federation of Pharmaceutical Industries & Assns Miscellaneous Commercial ServicesCommercial Services Operates as a trade association which promotes pharmaceutical discovery and development | Directeur/Membre du Conseil | - |
| Sociétés | Poste | Fin |
|---|---|---|
| LAKEFRONT BIOTHERAPEUTICS NV | Directeur/Membre du Conseil | 28/07/2025 |
| MERCK KGAA | Corporate Officer/Principal | 01/06/2025 |
| ALMIRALL, S.A. | Directeur Général | 31/12/2020 |
| SANOFI | Corporate Officer/Principal | 01/08/2017 |
Merck Healthcare KGaA
Merck Healthcare KGaA Pharmaceuticals: MajorHealth Technology Engages in discovering, developing and delivering of science-driven therapies for cancer patients | Directeur Général | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 11 |
|---|---|
Merck KGaA
Merck KGaA Pharmaceuticals: MajorHealth Technology Engages in the manufacturing of pharmaceutical and chemical products | Health Technology |
Sanofi
Sanofi Pharmaceuticals: MajorHealth Technology Engages in research, development and production of pharmaceuticals & vaccines | Health Technology |
Ipsen SA
Ipsen SA Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Galapagos NV
Galapagos NV BiotechnologyHealth Technology Manufactures and develops pharmaceutical products for oncology | Health Technology |
Almirall SA
Almirall SA Pharmaceuticals: MajorHealth Technology Engages in the development, manufacture and sale of pharmaceuticals | Health Technology |
Ghent University
Ghent University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sanofi-Aventis Deutschland GmbH
Sanofi-Aventis Deutschland GmbH Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products & provides research and development services | Health Technology |
European Federation of Pharmaceutical Industries & Assns
European Federation of Pharmaceutical Industries & Assns Miscellaneous Commercial ServicesCommercial Services Operates as a trade association which promotes pharmaceutical discovery and development | Commercial Services |
Smithkline Beecham | |
Vicore Pharma Holding AB
Vicore Pharma Holding AB Pharmaceuticals: MajorHealth Technology Engages in research and development of drugs for lung diseases | Health Technology |
Merck Healthcare KGaA
Merck Healthcare KGaA Pharmaceuticals: MajorHealth Technology Engages in discovering, developing and delivering of science-driven therapies for cancer patients | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national